By Kelly Cloonan

Shares of Artivion declined as the company disclosed plans to acquire Endospan and cut its full-year outlook.

The stock slid 23% to $27.30 in after-hours trading on Thursday. Through market close, shares are down 22% year to date.

The cardiac and vascular surgery company said it exercised its option to acquire Endospan after the company received premarket approval from the Food and Drug Administration for its Nexus Aortic Arch System.

The agreement provides for a base purchase price of $175 million, which Artivion has elected to pay entirely in cash. Artivion expects the net purchase price, after offsetting the loans under an amended and restated loan agreement, to be about $135 million.

Artivion could also pay up to $200 million in contingent consideration based on the future performance of Endospan's Nexus product, which would be payable about two years following after the close of the acquisition.

Artivion expects the deal to close in the second quarter. The acquisition aims to expand its aortic arch portfolio and broaden its pipeline with three additional programs with premarket approval.

The company also reported first-quarter profit and revenue that missed Wall Street's expectations, and cut its full-year outlook.

Artivion swung to a first-quarter profit of $1.4 million, or 3 cents a share, compared with a loss of $505,000, or 1 cent a share, a year earlier.

Adjusted earnings per share were 8 cents, missing estimates of 12 cents a share according to analysts polled by FactSet.

Revenue rose 18% to $116.3 million, missing analyst estimates of $115.7 million.

For 2026, the company now forecasts revenue of $480 million to $496 million, down from a prior range of $486 million to $504 million.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 07, 2026 18:01 ET (22:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.